Miryam Kerner

Miryam Kerner

Auto-generated profile, based on publicly available information

Miryam Kerner

Department of Dermatology, Haemek Medical Center, Afula, Israel

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2015 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
Eran Cohen-BarakEran Cohen-Barak
Eran Cohen-Barak
MKMiryam Kerner
Miryam Kerner
DRDganit Rozenman
Dganit Rozenman
MZMichael Ziv
Michael Ziv
Combination therapy has become important in treating psoriasis, using synergism between different mechanisms to maximize efficacy and minimize toxicity. Little has been published on the combination of cyclosporine and anti-tumor necrosis factor (TNF) α agents. In this study, a retrospective chart review was made of the effects of this combination therapy in 10 patients with recalcitrant psoriasis. Treatment included a conditioning phase with cyclosporine, 3.14 ± 0.37 mg/kg for 4.6 ± 2 weeks, and a combination phase during which etanercept/adalimumab were initiated and cyclosporine was tapered over 10.2 ± 3.7 weeks. Treatment success, evaluated after each phase, was classified as complete recovery (CR, more than 75% improvement), partial response (PR, 25-75% improvement), and no response (NR, less than 25% improvement). All patients reached CR at the end of the combination therapy. Two were still on combination therapy after 12 and 20 weeks. Adverse event occurred in three cases, all in the conditioning phase. We conclude that combination therapy with cyclosporine and anti-TNF α appears to offer an effective and safe approach to treatment of psoriasis.

1 June 2008
Verified
Journal Article
Closed access
MKMiryam Kerner
Miryam Kerner
MZMichael Ziv
Michael Ziv
FAFuad Abu-Raya
Fuad Abu-Raya
EHEinav Horowitz
Einav Horowitz
DRDganit Rozenman
Dganit Rozenman